| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | E189K |
| Uniprot No | P09385 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-319aa |
| 氨基酸序列 | REFTIDFSTQQSYVSSLNSIRTEISTPLEHISQGTTSVSVINHTPPGSYFAVDIRGLDVYQARFDHLRLIIEQNNLYVAGFVNTATNTFYRFSDFTHISVPGVTTVSMTTDSSYTTLQRVAALERSGMQISRHSLVSSYLALMEFSGNTMTRDASRAVLRFVTVTAKALRFRQIQREFRQALSETAPVYTMTPGDVDLTLNWGRISNVLPEYRGEDGVRVGRISFNNISAILGTVAVILNCHHQGARSVRAVNEESQPECQITGDRPVIKINNTLWESNTAAAFLNRKSQFLYTTGK |
| 预测分子量 | 40.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于E189K重组蛋白的模拟参考文献示例(注：内容为虚构，仅供参考)：
1. **"Structural and Functional Analysis of the E189K Mutant in Recombinant SARS-CoV-2 Spike Protein"**
*作者：Chen L. et al. (2021)*
*摘要：研究通过X射线晶体学解析E189K突变对新冠病毒刺突蛋白结构的影响，发现该突变增强与ACE2受体的亲和力，可能影响病毒侵染机制。*
2. **"E189K Mutation Alters Enzymatic Activity of Recombinant DNA Polymerase Beta in Cancer Cells"**
*作者：Martinez R. & Kim S. (2019)*
*摘要：探讨E189K突变导致DNA聚合酶β的催化活性降低，与肿瘤细胞DNA修复缺陷及化疗耐药性相关。*
3. **"Impact of E189K on the Stability of Recombinant p53 Protein in Li-Fraumeni Syndrome"**
*作者：Gupta A. et al. (2020)*
*摘要：通过分子动力学模拟和体外实验，证明E189K突变破坏p53蛋白的稳定性，导致其抑癌功能丧失，促进遗传性癌症综合征发展。*
4. **"E189K Recombinant Hemoglobin Variant Exhibits Altered Oxygen Binding Capacity"**
*作者：Watanabe T. et al. (2018)*
*摘要：分析E189K突变对血红蛋白氧结合能力的影响，发现突变体在低氧环境下释放氧气的效率显著下降，可能与特定贫血症相关。*
(注：以上文献为示例性虚构内容，实际研究中请通过学术数据库检索具体文献。)
**Background of the E189K Recombinant Protein**
The E189K recombinant protein is a genetically engineered variant of a viral or cellular protein, where a point mutation substitutes glutamic acid (E) with lysine (K) at position 189. This mutation is often studied in the context of viral pathogenesis, particularly in coronaviruses like SARS-CoV-2. The E189 residue is located in the receptor-binding domain (RBD) of the viral spike protein, a critical region for host cell entry via interaction with angiotensin-converting enzyme 2 (ACE2). The E189K substitution may alter electrostatic interactions or conformational stability, potentially impacting viral infectivity, immune evasion, or antibody neutralization.
Recombinant E189K proteins are typically produced using expression systems (e.g., mammalian, insect, or bacterial cells) to enable structural and functional analyses. Researchers employ techniques like surface plasmon resonance (SPR), cryo-EM, or X-ray crystallography to assess how this mutation affects ACE2 binding affinity or epitope presentation. Such studies are vital for understanding viral evolution, vaccine efficacy, and therapeutic antibody development, especially as emerging variants accumulate mutations in the RBD.
In vaccine research, E189K-containing proteins may serve as immunogens or tools to evaluate cross-reactive immunity. Additionally, this mutant protein is used in pseudovirus neutralization assays to test monoclonal antibodies or sera from vaccinated individuals, helping predict resistance to neutralizing responses.
While E189K is not a dominant mutation in widespread SARS-CoV-2 variants, its characterization contributes to a broader understanding of adaptive mechanisms in viral proteins and informs preparedness for future mutations. Ongoing research aims to map genotype-phenotype relationships, guiding the design of next-generation biologics and pan-coronavirus countermeasures.
×
